{"id":74963,"date":"2026-08-17T12:57:22","date_gmt":"2026-08-17T04:57:22","guid":{"rendered":"https:\/\/flcube.com\/?p=74963"},"modified":"2026-08-17T12:57:23","modified_gmt":"2026-08-17T04:57:23","slug":"yiling-pharmaceutical-files-ind-in-china-for-lb220-d08-a-first-in-class-factor-b-inhibitor-for-ahus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=74963","title":{"rendered":"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Yiling Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002603:SHE\">SHE: 002603<\/a>) announced that it has submitted an <strong>Investigational New Drug (IND) application in China<\/strong> for <strong>LB220\u2011D08<\/strong>, its independently developed small\u2011molecule candidate for the treatment of <strong>atypical hemolytic uremic syndrome (aHUS)<\/strong>. The filing marks the company&#8217;s entry into the complement\u2011mediated rare disease space.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>China NMPA<\/td><\/tr><tr><td><strong>Submission Type<\/strong><\/td><td>IND application<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LB220\u2011D08 (Class 1 innovative chemical drug)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Atypical hemolytic uremic syndrome (aHUS)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>13 Aug 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>IND review clearance; initiation of clinical development in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>LB220\u2011D08<\/strong>, an innovative <strong>novel small\u2011molecule chemical drug<\/strong>, designated a <strong>Class 1 innovative chemical drug<\/strong> with proprietary intellectual property rights, independently developed by <strong>Yiling Pharmaceutical<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> Selectively targets <strong>Factor B<\/strong>, a key component of the <strong>alternative complement pathway<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Inhibits the alternative complement pathway and blocks activation of <strong>C3 convertase<\/strong>, preventing the generation of toxins <strong>C3a and C5a<\/strong> and the formation of <strong>C5 convertase<\/strong> and the <strong>membrane attack complex (MAC, C5b\u20119)<\/strong><\/li>\n\n\n\n<li><strong>Selectivity Advantage:<\/strong> Preserves normal physiological functions of the <strong>lectin and classical complement pathways<\/strong>, potentially offering a more targeted safety profile versus broader complement inhibition<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-background-ahus\" class=\"wp-block-heading\">Disease Background \u2013 aHUS<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease<\/strong><\/td><td>Atypical hemolytic uremic syndrome (aHUS)<\/td><\/tr><tr><td><strong>Nature<\/strong><\/td><td>Rare, life\u2011threatening complement\u2011mediated thrombotic microangiopathy<\/td><\/tr><tr><td><strong>Pathophysiology<\/strong><\/td><td>Uncontrolled activation of the alternative complement pathway drives thrombosis, hemolysis, and organ damage, particularly in the kidneys<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>High cost of existing complement\u2011targeted biologics and lifelong treatment burden leave room for differentiated oral alternatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Disease Opportunity:<\/strong> aHUS is a rare but severe complement\u2011mediated disorder with limited treatment options; a targeted small\u2011molecule approach could address significant unmet need.<\/li>\n\n\n\n<li><strong>Mechanism Differentiation:<\/strong> By selectively inhibiting <strong>Factor B<\/strong> while sparing the lectin and classical pathways, <strong>LB220\u2011D08<\/strong> is designed to suppress disease\u2011driving complement activity without broad immunosuppression \u2014 a profile that, if validated clinically, could differentiate it from existing C5\u2011targeting antibodies.<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> The IND filing extends <strong>Yiling Pharmaceutical&#8217;s<\/strong> pipeline beyond its established franchises into innovative chemical drugs and complement\u2011mediated rare diseases.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> With proprietary intellectual property and Class 1 designation, the program positions Yiling to compete in the fast\u2011evolving Factor B inhibitor landscape, where global interest in oral complement therapies continues to grow.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review, clinical development, and commercial potential for LB220\u2011D08. Actual results may differ due to risks including IND clearance outcomes, clinical trial results, and competitive dynamics in the complement inhibitor market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4ee5\u5cad\u836f\u4e1a\uff1a\u5173\u4e8e\u5316\u836f\u521b\u65b0\u836fLB220-D08\u7f13\u91ca\u7247\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4ee5\u5cad\u836f\u4e1a\uff1a\u5173\u4e8e\u5316\u836f\u521b\u65b0\u836fLB220-D08\u7f13\u91ca\u7247\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-cc0ab26b-ec09-4a45-8793-e19541e0be6f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4ee5\u5cad\u836f\u4e1a\uff1a\u5173\u4e8e\u5316\u836f\u521b\u65b0\u836fLB220-D08\u7f13\u91ca\u7247\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u4ee5\u5cad\u836f\u4e1a\uff1a\u5173\u4e8e\u5316\u836f\u521b\u65b0\u836fLB220-D08\u7f13\u91ca\u7247\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4ee5\u5cad\u836f\u4e1a\uff1a\u5173\u4e8e\u5316\u836f\u521b\u65b0\u836fLB220-D08\u7f13\u91ca\u7247\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cc0ab26b-ec09-4a45-8793-e19541e0be6f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[90,24,2072,2071],"class_list":["post-74963","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-filings","tag-rare-orphan-disease-drugs","tag-she-002603","tag-yiling-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application in China for LB220\u2011D08, its independently developed small\u2011molecule candidate for the treatment of atypical hemolytic uremic syndrome (aHUS). The filing marks the company&#039;s entry into the complement\u2011mediated rare disease space.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=74963\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS\" \/>\n<meta property=\"og:description\" content=\"Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application in China for LB220\u2011D08, its independently developed small\u2011molecule candidate for the treatment of atypical hemolytic uremic syndrome (aHUS). The filing marks the company&#039;s entry into the complement\u2011mediated rare disease space.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=74963\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T04:57:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T04:57:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74963#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74963\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS\",\"datePublished\":\"2026-08-17T04:57:22+00:00\",\"dateModified\":\"2026-08-17T04:57:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74963\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial filings\",\"Rare \\\/ orphan disease drugs\",\"SHE: 002603\",\"Yiling Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74963#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74963\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=74963\",\"name\":\"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-17T04:57:22+00:00\",\"dateModified\":\"2026-08-17T04:57:23+00:00\",\"description\":\"Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application in China for LB220\u2011D08, its independently developed small\u2011molecule candidate for the treatment of atypical hemolytic uremic syndrome (aHUS). The filing marks the company's entry into the complement\u2011mediated rare disease space.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74963#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74963\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74963#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS - Insight, China&#039;s Pharmaceutical Industry","description":"Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application in China for LB220\u2011D08, its independently developed small\u2011molecule candidate for the treatment of atypical hemolytic uremic syndrome (aHUS). The filing marks the company's entry into the complement\u2011mediated rare disease space.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=74963","og_locale":"en_US","og_type":"article","og_title":"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS","og_description":"Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application in China for LB220\u2011D08, its independently developed small\u2011molecule candidate for the treatment of atypical hemolytic uremic syndrome (aHUS). The filing marks the company's entry into the complement\u2011mediated rare disease space.","og_url":"https:\/\/flcube.com\/?p=74963","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-17T04:57:22+00:00","article_modified_time":"2026-08-17T04:57:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=74963#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=74963"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS","datePublished":"2026-08-17T04:57:22+00:00","dateModified":"2026-08-17T04:57:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=74963"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial filings","Rare \/ orphan disease drugs","SHE: 002603","Yiling Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=74963#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=74963","url":"https:\/\/flcube.com\/?p=74963","name":"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-17T04:57:22+00:00","dateModified":"2026-08-17T04:57:23+00:00","description":"Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application in China for LB220\u2011D08, its independently developed small\u2011molecule candidate for the treatment of atypical hemolytic uremic syndrome (aHUS). The filing marks the company's entry into the complement\u2011mediated rare disease space.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=74963#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=74963"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=74963#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yiling Pharmaceutical Files IND in China for LB220-D08, a First-In-Class Factor B Inhibitor for aHUS"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=74963"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74963\/revisions"}],"predecessor-version":[{"id":74966,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74963\/revisions\/74966"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=74963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=74963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=74963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}